Menu
MorphoSys US

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2020

  1. 17/09/2020
    MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
  2. 17/09/2020
    MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
  3. 18/08/2020
    National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
  4. 05/08/2020
    MorphoSys Reports Second Quarter and First Half 2020 Results
  5. 01/08/2020
    FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  6. 01/08/2020
    MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  7. 30/07/2020
    Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020
  8. 14/07/2020
    MorphoSys' Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
  9. 02/06/2020
    MorphoSys to Present at Upcoming Virtual Investor Conferences
  10. 27/05/2020
    MorphoSys AG Reports Outcome of Annual General Meeting 2020

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2020

  1. 01/08/2020
    MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  2. 13/01/2020
    MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
    No download available

2019

  1. 18/11/2019
    Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
    No download available
  2. 29/10/2019
    MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
    No download available
  3. 28/10/2019
    MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
    No download available
  4. 03/07/2019
    Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
    No download available
  5. 24/06/2019
    Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  6. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  7. 16/05/2019
    MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
    No download available
  8. 19/02/2019
    Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
    No download available

Pages

Presentations
and conferences

Tuesday, September 29, 2020 - 9:00am
Conference Call and Webcast: MorphoSys & Incyte Tafasitamab Expert Event

MorphoSys and Incyte will host a joint conference call and webcast to discuss global development, unmet need and commercial opportunities for tafasitamab. The conference call and webcast is scheduled for Tuesday, September 29, 2020 at 9:00 am EDT, (3:00 pm CEST).

Date of the conference call and Webcast: Tuesday, September 20, 2020
Time: 9:00 am EDT, (3:00 pm CEST)

Dial-in numbers:
Germany: +49 69 201 744 220
United Kingdom: +44 203 009 2470 
USA: +1 877 423 0830

Participant PIN: 83557299#

Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.
Go to Webcast (slides only)
Got to Webcast (audio and slides)
A replay of the conference will also be available at the corporate website following the live event.

Archive

Date
Title
MP3

2020

  1. 08/06/2020

    Conference Call and Webcast: Q2/H1 2020 Financial Results

  2. 08/03/2020

    Joint MorphoSys and Incyte Conference Call

  3. 06/18/2020

    Webcast: JMP Securities Hematology and Oncology Forum

  4. 06/10/2020

    Webcast: Goldman Sachs 41st Annual Global Healthcare Conference

  5. 06/03/2020

    Webcast: Jefferies 2020 Healthcare Conference

  6. 05/07/2020

    Conference Call and Webcast: Q1 2020 Financial Results

  7. 03/19/2020

    Conference Call and Webcast: Year End 2019

  8. 02/26/2020

    Webcast: 9th Annual SVB Leerink Global Healthcare Conference

  9. 01/15/2020

    Webcast: 38th Annual J.P. Morgan Healthcare Conference

  10. 01/13/2020

    Joint Conference Call MorphoSys and Incyte on the Global Collaboration and License Agreement for Tafasitamab

2019

  1. 12/03/2019

    31st Annual Piper Jaffray Healthcare Conference

  2. 11/25/2019

    Presentation: German Eigenkapitalforum

  3. 10/30/2019

    Conference Call and Webcast: Q3 2019 Financial Results

Pages

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".

 

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No